ClinicalTrials.gg
Active, not recruitingNCT03587740Updated May 18, 2026Results posted

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

A Phase 2 interventional study of T-DM1 in Breast Cancer, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 14 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.

Enrollment
26th of 56
111 · median 103
Started
2018
with 1 other
Phase 2
26 of 56
9 open now
Primary completion
2025-03
later than 2 of 15 live
Registered
41st of 56
by date
Lead sponsor
6 of 56
Dana-Farber Cancer Institute

Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 26th largest by enrollment, is one of 2 that started in 2018, is one of 26 in phase 2, reaches primary completion later than 2 of the 15 other live ones, and was the 41st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About Ado-Trastuzumab Emtansine

Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, or all of them as a file.
02

Study summary

This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer.

The drug involved in this study is:

-ado-trastuzumab emtansine (T-DM1)

Read the detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied and research doctors are trying to find out more about it-such as the safest dose to use and the side effects it may cause.

The purpose of this research study is to examine the long-term benefits of T-DM1 with regard to breast cancer and take a closer look at the side effects experienced by participants receiving T-DM1.

The FDA (the U.S. Food and Drug Administration) has not approved T-DM1 for use in patients with stage I, II, or III breast cancer, but it has been approved for use in advanced, previously treated, HER2-positive breast cancer.

T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy. More specifically, the trastuzumab in T-DM1 first binds to the HER2 protein on the surface of the breast cancer cells and the DM1 then enters the cells and can cause them to die, preventing tumor growth

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed -positive disease by local pathology, defined as immunohistochemistry (IHC) 3+ or amplification by FISH (HER2/CEP17 ratio ≥2 or an average of ≥6 HER2 gene copies per nucleus) AND confirmed by Central Pathology Review (Dr. Deborah Dillon at Brigham and Women's Hospital, Boston, MA) prior to patient being registered to begin protocol therapy. See section 3.4. http://ascopubs.org/doi/full/10.1200/jco.2013.50.9984
  • NOTE: DCIS components should not be counted in the determination of HER2 status.
  • Age ≥60 years at the time of study registration (men and women eligible)
  • Participants must have histologically or cytologically confirmed Stage I-III breast cancer with the following criteria met:
  • If node-negative or if node status unknown (because it was not assessed), tumor must be >5 mm of any hormone receptor subtype (document ER/PR status: if some ER/PR staining is present, ER and PR negative are defined as being positive in \<10% cells [per local pathology read]).
  • If node-positive (N1-N3), T1mi, T1a, T1b, T1c, T2, or T3 tumors are eligible (see below for further details on defining node-negative disease) Definition of node-negative disease (when node status known): If the patient has had a negative sentinel node and/or a negative axillary dissection, then the patient is determined to be node-negative. Axillary nodes with single cells or tumor clusters ≤ 0.2 mm by either H\&E or IHC will be considered node-negative. Any axillary lymph node with tumor clusters between 0.02 and 0.2cm is considered a micrometastasis. Patients with a micrometastasis are eligible even if their tumor is \</= 5mm. An axillary dissection is not required to be performed in patients with a positive sentinel node and management of the axilla will be left up to the treating provider. In cases where the specific pathologic size of lymph node involvement is subject to interpretation, the principal investigator will make the final determination as to eligibility. In these special situations, the investigator must document this approval in the patient medical record.
  • ER/PR determination assays performed by IHC methods according to the local institution standard protocol.
  • Standard chemotherapy/trastuzumab declined by patient OR patient is deemed by physician for any reason to not be a candidate for standard therapy (i.e. patient and/or provider choose not to pursue standard trastuzumab-based chemotherapy regimen because of concerns related to toxicity or provider/patient preference).
  • For patients with bilateral or multifocal/multicentric breast cancers, one of the following criteria must be met to enroll: (1) each cancer individually meets criteria for enrollment (only ONE tumor has to undergo central confirmation for HER2), (2) at least one tumor meets eligibility (per tumor size/nodes/subtype outlined above) and the other foci in the ipsilateral or contralateral breast are also HER2-positive but are too small for enrollment (e.g., a patient is eligible if a cancer is T2N0 and HER2-positive in one breast, but the contralateral breast has a T1a HER2+ cancer that isn't eligible on its own, (3) there is at least one qualifying tumor of >5mm but there are other small foci of disease that are too small to test for ER/PR/HER2 and are felt to be a part of the same tumor or similar tumor, OR (4) at least one tumor meets eligibility and the other foci in the ipsilateral or contralateral breast are HER2-negative and do not meet criteria for chemotherapy per provider discretion (e.g. if a patient has a HER2-positive tumor meeting eligibility but also has a second, HER2-negative, small, node-negative, ER+, low grade cancer present, she is still eligible for enrollment). However, in the specific case that a second breast cancer is stage III and HER2-negative, that patient is excluded (because the second cancer is high-risk and likely will require non-HER2-directed therapy).
  • All tumor removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy).
  • NOTE: Management of axillary lymph nodes is up to the treating provider; however, all surgical margins should be clear of invasive cancer or DCIS (i.e., no tumor on ink). The local pathologist must document negative margins of resection in the pathology report. If all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed. Likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removed.

    -≤90 days from the patient's most recent breast surgery for this breast cancer. Note: In cases where registration will occur >90 days from surgery but within an acceptable time frame, patient may be eligible for enrollment with approval from the PI, Rachel Freedman MD, MPH.

  • Performance Status (PS) 0-2. See Appendix F.
  • Baseline ≥50% by MUGA scan or echocardiogram performed ≤60 days prior to registration.
  • The following laboratory values obtained ≤14 days prior to registration:

    • (ANC) ≥1500/mm3
    • count ≥100,000/mm3
    • >9.0 g/dL
    • Total ≤1.5 x (ULN). If patient has known Gilbert's syndrome, the suggested threshold for treatment is a total bilirubin ≤2.0 x ULN, but will be left to the treating providers discretion.
    • and ALT ≤2.5 x ULN, alkaline phosphatase ≤2.5 x ULN
    • \<1.5 x ULN for institution unless patient is on planned therapy with anticoagulants (i.e., warfarin) with higher target planned. In those cases, INR up to 3.5 is acceptable.
    • PTT \<1.5 x ULN for institution unless patient is on planned therapy with heparin or heparin-like products Note: In the case of longstanding ethnic neutropenia, patient may be eligible for enrollment with approval from the PI, Rachel Freedman MD, MPH.
  • >5 years per provider's assessment
  • Willing to employ adequate and appropriate if applicable
  • NOTE: This study is for patients aged 60 and older, and most female patients will have entered menopause by this time; however patients should not become pregnant while on this study because T-DM1 can affect an unborn baby. Pre-menopausal women need to use birth control while on this study and women should not breastfeed a baby while on this study. Any man treated on this study will also need to use contraception if his partner is a premenopausal female. Patients should check with their health care provider about what kind of birth control methods to use and how long to use them.
  • Negative urine or serum pregnancy test done ≤7 days prior to registration, for women of only
  • NOTE: In the rare case that a woman enrolling on study is of childbearing potential, a pregnancy test is required prior to enrollment on study.
  • Able to provide informed written consent.
  • Willing to return to consenting institution for follow-up at 6 months
  • Willing to provide blood samples for mandatory correlative research purposes.
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Evidence of disease.
  • Patients will not require baseline staging PET or CT chest, abdomen, pelvis or bone scan to rule out metastatic disease prior to enrollment. Any staging scans will be ordered at the treating provider's discretion. If metastatic disease is found on any staging studies done, patients will not be eligible for enrollment.
  • Locally advanced tumors at diagnosis (T4), including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid).
  • Patients with stage III, -negative cancer in the contralateral breast (see 3.1.6 above).
  • Positive (Hepatitis B surface antigen and antibody) and/or (Hepatitis C antibody test) as indicated by serologies conducted ≤3 months prior to registration if liver function tests are outside of the normal institutional range.

NOTE: A hepatitis panel is required of all participants as part of screening. Patients with positive Hepatitis B or C serologies indicating active infection without known active disease must meet the eligibility requirements for , AST, total , , PTT, and alkaline phosphatase on at least two consecutive occasions, separated by at least 1 week. Patients with laboratory evidence of vaccination to Hepatitis B (e.g., positive antibodies) are eligible.

  • Active liver disease, for example, due to hepatic disorder, or sclerosing cholangitis.
  • Significant, active cardiopulmonary dysfunction (i.e. uncontrolled heart issues)as indicated by or echocardiogram performed ≤60 days prior to registration and/or by presence of any of the following:

    • History of (Version 4.0) Grade ≥3 symptomatic congestive heart failure (CHF) or criteria Class ≥ II
    • Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or valvular disease
    • High-risk uncontrolled arrhythmias (i.e., atrial tachycardia with a heart rate > 100/min at rest, significant ventricular arrhythmia [ventricular tachycardia], or higher-grade atrioventricular [AV]-block [second degree AV-block Type 2 [Mobitz 2] or third degree AV-block]); if adequately and safely treated, patient may be eligible.
    • Significant symptoms (Grade ≥ 2) relating to left ventricular dysfunction, cardiac arrhythmia, or cardiac ischemia
    • Myocardial infarction within 12 months prior to registration
    • Uncontrolled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure >100 mmHg)
    • Evidence of transmural infarction on
    • Requirement for oxygen therapy
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.
  • Currently receiving any other agent which would be considered as a treatment for the primary neoplasm.
  • Concurrent second or past malignancy with >30% estimated risk of relapse in next 5 years. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix in addition to smoldering pre-malignant or malignant conditions with minimized concern for clinical progression during treatment such as MGUS or CLL, based on treating provider's assessment. -NOTE: If there is a history or prior malignancy, patient must not be receiving active treatment for this malignancy cancer.
  • Any prior treatment with T-DM1 or any trastuzumab therapy.
  • Any chemotherapy for this breast cancer.

    ->90 days of tamoxifen therapy, or other hormonal therapy, for adjuvant therapy for this malignancy

  • NOTE: If the patient has received \<90 days of such therapy but is still receiving it at the time of entry into the study, patient must temporarily stop the therapy prior to Cycle 1 Day 1. The therapy can re-start only after 6 weeks of T-DM1 have been administered (anytime after C3D1).
  • History of exposure at any time to the following cumulative doses of anthracyclines:

    • Doxorubicin or liposomal doxorubicin >500mg/m2.
    • Epirubicin >900mg/m2.
    • Mitoxantrone >120 mg/m2.
    • Another anthracycline, or more than one anthracycline used in a cumulative dose exceeding the equivalent of doxorubicin 500mg/m2.
  • History of intolerance (including Grade 3 or 4 infusion reactions) to murine proteins.
  • History of previous invasive breast cancer ≤5 years.
  • NOTE: History of DCIS, LCIS is allowed.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    T-DM1

    T-DM1 will be administered every 3 weeks intravenously, with 21 consecutive days defined as a treatment.

    Drug: T-DM1

Interventions

  • DrugAdo-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.

    Also known as: Kadcyla

06

What researchers measure

Primary outcomes

  1. Invasive Disease-free Survival Rate (IDFS)

    IDFS is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, contralateral invasive breast cancer, or a second non-breast primary cancer, whichever occurs first. Patients without one of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods.

    Time frame: 5 years

Secondary outcomes

  1. Invasive Breast Cancer-free Survival (IBCFS)

    IBCFS is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, or contralateral invasive breast cancer, whichever occurs first. Patients who experience a second non-breast new primary outcome will be censored at their new primary diagnosis date. Patients without any of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods.

    Time frame: 5 years

  2. Recurrence-free Interval (RFI)

    RFI is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, or distant recurrence. Patients who experience other IDFS events, such as contralateral invasive breast cancer, a second non-breast primary cancer, or death due to any cause, will be censored at the time of these events. Patients without any of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods. Note: The protocol labels this outcome as recurrence-free survival (RFS). However, the definition provided in the protocol, where the recurrences are considered events but deaths are not considered events, matches the definition of recurrence-free interval (RFI) provided in the STEEP version 2.0 paper (Tolaney et al., 2021).

    Time frame: 5 years

  3. Overall Survival (OS)

    OS defined as the time from the first T-DM1 dose to death attributable to any cause (i.e. death from breast cancer, non-breast cancer cause, or from unknown cause). Subjects alive at the time of data analysis (including those lost to follow-up) will be censored at the last known alive date. Survival probabilities (reported as percentages) estimated from Kaplan Meier methods.

    Time frame: 5 years

  4. Site of First Recurrence

    The site of the first IDFS event for patients receiving T-DM1, which will be tabulated as frequencies and relative frequencies. IDFS events include ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, contralateral invasive breast cancer, or a second non-breast primary cancer.

    Time frame: 5 years

  5. Incidence Rate of All Toxicities (Safety)

    Among all patients who received at least one dose of T-DM1 treatment, summarize the maximum treatment-related adverse event reported per subject. Adverse events (AEs) are graded utilizing CTCAE v4.0; AEs of grade 2 to 5 are systematically reported, while grade 1 AEs are not systematically reported, so subjects with no reported AEs (grade 0) and subjects with a maximum grade 1 AE are combined into a single category. AEs are considered treatment-related if they start at or after the first dose of T-DM1 and are determined to be definitely, possibly, or probably related to T-DM1 treatment.

    Time frame: 2 years

  6. Incidence Rate of Cardiac-Related Adverse Events: Left Ventricular Systolic Dysfunction

    Incidence of symptomatic left ventricular systolic dysfunction in patients receiving T-DM1, recorded as frequencies and percentages.

    Time frame: 2 years

  7. Incidence Rate of Cardiac-Related Adverse Events: Cardiac Death

    Incidence of deaths due to a cardiac event in patients receiving T-DM1, recorded as frequencies and percentages.

    Time frame: 2 years

  8. Incidence Rate of Cardiac-Related Adverse Events: Decreased Ejection Fraction

    Incidence of a decrease in ejection fraction by at least 10 percentage points below baseline (measured by an absolute difference) or an ejection fraction below 50%.

    Time frame: 2 years

07

Results

Posted Apr 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneT-DM1
Started111
Completed111
Not completed0

Outcome measures

PrimaryInvasive Disease-free Survival Rate (IDFS)

IDFS is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, contralateral invasive breast cancer, or a second non-breast primary cancer, whichever occurs first. Patients without one of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods.

Time frame:
5 years
Reported as:
Number · Survival percent probability
Invasive Disease-free Survival Rate (IDFS)
Survival percent probabilityT-DM1
Survival percent probability at 5 years84.2 (77.1 to 92.0)
Survival percent probability at 3 years91.2 (85.9 to 96.9)
SecondaryInvasive Breast Cancer-free Survival (IBCFS)

IBCFS is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, or contralateral invasive breast cancer, whichever occurs first. Patients who experience a second non-breast new primary outcome will be censored at their new primary diagnosis date. Patients without any of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods.

Time frame:
5 years
Reported as:
Number · Survival percent probability
Invasive Breast Cancer-free Survival (IBCFS)
Survival percent probabilityT-DM1
Survival percent probability at 5 years92.0 (86.9 to 97.5)
Survival percent probability at 3 years94.1 (89.7 to 98.8)
SecondaryRecurrence-free Interval (RFI)

RFI is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, or distant recurrence. Patients who experience other IDFS events, such as contralateral invasive breast cancer, a second non-breast primary cancer, or death due to any cause, will be censored at the time of these events. Patients without any of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods. Note: The protocol labels this outcome as recurrence-free survival (RFS). However, the definition provided in the protocol, where the recurrences are considered events but deaths are not considered events, matches the definition of recurrence-free interval (RFI) provided in the STEEP version 2.0 paper (Tolaney et al., 2021).

Time frame:
5 years
Reported as:
Number · Survival percent probability
Recurrence-free Interval (RFI)
Survival percent probabilityT-DM1
Survival percent probability at 5 years94.9 (90.6 to 99.4)
Survival percent probability at 3 years95.9 (92.1 to 99.9)
SecondaryOverall Survival (OS)

OS defined as the time from the first T-DM1 dose to death attributable to any cause (i.e. death from breast cancer, non-breast cancer cause, or from unknown cause). Subjects alive at the time of data analysis (including those lost to follow-up) will be censored at the last known alive date. Survival probabilities (reported as percentages) estimated from Kaplan Meier methods.

Time frame:
5 years
Reported as:
Number · Survival percent probability
Overall Survival (OS)
Survival percent probabilityT-DM1
Survival percent probability at 5 years93.3 (88.1 to 98.9)
Survival percent probability at 3 years96.1 (92.4 to 99.9)
SecondarySite of First Recurrence

The site of the first IDFS event for patients receiving T-DM1, which will be tabulated as frequencies and relative frequencies. IDFS events include ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, contralateral invasive breast cancer, or a second non-breast primary cancer.

Time frame:
5 years
Reported as:
Count of participants · Participants
Site of First Recurrence
ParticipantsT-DM1
Ipsilateral invasive breast cancer1
Regional invasive breast cancer0
Contralateral invasive breast cancer3
Distant recurrence3
Non-breast new primary invasive cancer7
Death due to breast cancer2
Death due to other non-breast cancer reason1
Alive and event-free at last follow-up94
SecondaryIncidence Rate of All Toxicities (Safety)

Among all patients who received at least one dose of T-DM1 treatment, summarize the maximum treatment-related adverse event reported per subject. Adverse events (AEs) are graded utilizing CTCAE v4.0; AEs of grade 2 to 5 are systematically reported, while grade 1 AEs are not systematically reported, so subjects with no reported AEs (grade 0) and subjects with a maximum grade 1 AE are combined into a single category. AEs are considered treatment-related if they start at or after the first dose of T-DM1 and are determined to be definitely, possibly, or probably related to T-DM1 treatment.

Time frame:
2 years
Reported as:
Count of participants · Participants
Incidence Rate of All Toxicities (Safety)
ParticipantsT-DM1
Grade 0 (no toxicity) or grade 1 (mild)20
Grade 2 (moderate)59
Grade 3 (severe)31
Grade 4 (life-threatening)1
Grade 5 (death related to toxicity)0
SecondaryIncidence Rate of Cardiac-Related Adverse Events: Left Ventricular Systolic Dysfunction

Incidence of symptomatic left ventricular systolic dysfunction in patients receiving T-DM1, recorded as frequencies and percentages.

Time frame:
2 years
Reported as:
Count of participants · Participants
Incidence Rate of Cardiac-Related Adverse Events: Left Ventricular Systolic Dysfunction
ParticipantsT-DM1
Symptom of left ventricular systolic dysfunction observed4
No symptom of left ventricular systolic dysfunction observed107
SecondaryIncidence Rate of Cardiac-Related Adverse Events: Cardiac Death

Incidence of deaths due to a cardiac event in patients receiving T-DM1, recorded as frequencies and percentages.

Time frame:
2 years
Reported as:
Count of participants · Participants
Incidence Rate of Cardiac-Related Adverse Events: Cardiac Death
ParticipantsT-DM1
Cardiac death0
Death not observed in follow-up or death due to non-cardiac cause111
SecondaryIncidence Rate of Cardiac-Related Adverse Events: Decreased Ejection Fraction

Incidence of a decrease in ejection fraction by at least 10 percentage points below baseline (measured by an absolute difference) or an ejection fraction below 50%.

Time frame:
2 years
Reported as:
Count of participants · Participants
Incidence Rate of Cardiac-Related Adverse Events: Decreased Ejection Fraction
ParticipantsT-DM1
Decrease in ejection fraction by at least 10 percentage points below baseline11
Ejection fraction decreased below 50%1
No ejection fraction cardiac toxicity observed99

Adverse events

Collected over Adverse Events were assessed up to 2 years. Deaths were assessed up to 5 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-DM16/111 (5.4%)17/111 (15.3%)111/111 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventT-DM1
FeverGeneral disorders2/111
Lung infectionInfections and infestations2/111
FallInjury, poisoning and procedural complications2/111
AnemiaBlood and lymphatic system disorders1/111
ColitisGastrointestinal disorders1/111
Gastric hemorrhageGastrointestinal disorders1/111
Gastrointestinal disorders - Other, specifyGastrointestinal disorders1/111
FatigueGeneral disorders1/111
Hepatobiliary disorders - Other, specifyHepatobiliary disorders1/111
Bladder infectionInfections and infestations1/111
Most frequent other events
Showing 10 of 195
Most frequent other events
EventT-DM1
FatigueGeneral disorders92/111
Aspartate aminotransferase increasedInvestigations82/111
NauseaGastrointestinal disorders65/111
Peripheral sensory neuropathyNervous system disorders64/111
Dry mouthGastrointestinal disorders62/111
Alanine aminotransferase increasedInvestigations56/111
AnorexiaMetabolism and nutrition disorders53/111
EpistaxisRespiratory, thoracic and mediastinal disorders53/111
Platelet count decreasedInvestigations52/111
MyalgiaMusculoskeletal and connective tissue disorders50/111

Baseline characteristics

Participants who received at least one dose of T-DM1 treatment

Age, Continuous
Age, Continuous(Years)T-DM1
Median71 (60 to 88)
Age, Customized
Age, Customized(Participants)T-DM1
Age at enrollment — 60 to 65 years33
Age at enrollment — 66 to 70 years22
Age at enrollment — 71 to 75 years25
Age at enrollment — 76 to 80 years18
Age at enrollment — Over 80 years13
Sex: Female, Male
Sex: Female, Male(Participants)T-DM1
Female102
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)T-DM1
Hispanic or Latino2
Not Hispanic or Latino83
Unknown or Not Reported26
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)T-DM1
Race — Asian3
Race — Black or African American5
Race — White79
Race — Other or Unknown24
ECOG Performance Status
ECOG Performance Status(Participants)T-DM1
0 (fFully active; able to carry out all pre-disease activities without restriction)88
1 (Restricted in physically strenuous activity, but ambulatory and able to carry out light work)21
2 (Ambulatory and capable of all self-care, but unable to carry out any work activities)2
Clinical stage at primary breast cancer diagnosis
Clinical stage at primary breast cancer diagnosis(Participants)T-DM1
Stage I77
Stage II29
Stage III5
Tumor size (cm) - largest pathologic focus of primary invasive tumor
Tumor size (cm) - largest pathologic focus of primary invasive tumor(Participants)T-DM1
<1 cm22
1-2 cm56
2-5 cm29
>5 cm4

1 further baseline measures are reported on the registry.

08

Study locations

14 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Mar 2025, 78 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 78 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2018
First posted
Jul 16, 2018
StartActual
Aug 22, 2018
Primary completionActual
Mar 3, 2025
CompletionEst.
Aug 30, 2027
Results first posted
Apr 29, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03587740
Collaborators
Susan G. Komen Breast Cancer Foundation, Gateway for Cancer Research
Responsible party
Rachel Freedman, MD, MPH (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Jul 16, 2018
Start date
Aug 22, 2018
Primary completion
Mar 3, 2025
Completion
Aug 30, 2027 (estimated)
Results posted
Apr 29, 2026
Last update
May 18, 2026

Study contacts

Rachel Freedman, MD MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ado-Trastuzumab Emtansine

Start the discussion